Discovery of tuberculosis bacterium enzyme paves way for new TB drugs

Mar 27, 2009

A team of University of Maryland scientists has paved the way for the development of new drug therapies to combat active and asymptomatic (latent) tuberculosis infections by characterizing the unique structure and mechanism of an enzyme in M. tuberculosis, the bacterium that causes the disease. Assistant Professor of Chemistry and Biochemistry Barbara Gerratana, in the university's College of Chemical and Life Sciences, led the research team, which included her graduate student Melissa Resto and Assistant Professor Nicole LaRonde-LeBlanc.

"The NAD+ synthetase enzyme that our study describes is absolutely essential for the survival of the bacteria and an important drug target. We can now use the information we have about its structure and mechanism to develop inhibitors for this enzyme," Gerratana explained.

The study, titled "Regulation of active site coupling in glutamine-dependent NAD+ synthetase," was published in on March 8, 2009 in Nature Structural & Molecular Biology.

The development of new drugs to combat tuberculosis (TB) has become urgent, as strains of TB resistant to all major anti-TB drugs have emerged worldwide. The World Health Organization estimates that one third of the world's population is asymptomatically infected with TB and that ten percent will eventually develop the disease.

According to other leading TB researchers, these new findings from Gerratana and her colleagues will be extremely valuable for the design of structure-based inhibitors specific for M. tuberculosis NAD+ synthetase and may lead to the development of new drugs to combat and eliminate the disease.

"NadE [NAD+ synthetase] represents one of a small handful of TB drug targets that has iron-clad validation, the lack of a crystal structure was the only serious impediment to drug development and this study represents a hugely important step forward" said Clifton E. Barry, Chief of the Tuberculosis Research Section of the Intramural Research Division of the National Institute of Allergy and Infectious Diseases. "Inhibiting NadE even kills non-replicating cells, so this discovery may well benefit the one-third of the human population that carries latent bacteria."

NAD+ synthetase is responsible for making NAD+, a coenzyme found in all living cells that is involved in regulating many cellular processes and in reduction-oxidation metabolic reactions. More than one biosynthetic pathway is usually involved in NAD+ production. In humans, NAD+ can be obtained through several different complex pathways, and not all of the pathways utilize NAD+ synthetase to produce NAD+. Unlike in humans, however, there are only two pathways involved in producing NAD+ in the tuberculosis and both depend on the activity of NAD+ synthetase to obtain NAD+.

"We are optimistic about the potential for developing new drugs that will effectively target this enzyme in TB and minimize side effects to humans, since we have NAD+ biosynthetic pathways that are independent of the NAD+ synthetase activity," Gerratana said.

The World Health Organization reports that a new instance of TB infection occurs every second. Current treatment of tuberculosis targets the active tuberculosis bacterium and has little effect on the non-replicating bacterium. "If we don't tackle latent tuberculosis, this disease will not be eradicated," Gerratana said.

Source: University of Maryland (news : web)

Explore further: Cell division, minus the cells

add to favorites email to friend print save as pdf

Related Stories

Tuberculosis drug shows promise against latent bacteria

Sep 12, 2008

A new study has shown that an investigational drug (R207910, currently in clinical trials against multi-drug resistant tuberculosis strains) is quite effective at killing latent bacteria. This revelation suggests that R207910 ...

Experts say Toronto unprepared for TB

Feb 24, 2008

Health experts warn there could be an outbreak of tuberculosis in Toronto, which reportedly lacks a centralized system of TB clinics.

Experimental TB drug explodes bacteria from the inside out

Nov 27, 2008

An international team of biochemists has discovered how an experimental drug unleashes its destructive force inside the bacteria that cause tuberculosis (TB). The finding could help scientists develop ways to treat dormant ...

WHO warns of drug-resistant TB

Sep 06, 2006

The World Health Organization in Switzerland has warned of a new strain of tuberculosis that is rapidly spreading and cannot be treated with current drugs.

Smoking increases risk of TB infection, study finds

Feb 27, 2007

People who smoke have a greater risk of becoming infected with tuberculosis (TB) and of having that infection turn into active TB disease, according to an analysis by researchers at the University of California, Berkeley.

Recommended for you

Cell division, minus the cells

2 minutes ago

(Phys.org) —The process of cell division is central to life. The last stage, when two daughter cells split from each other, has fascinated scientists since the dawn of cell biology in the Victorian era. ...

A new method simplifies the analysis of RNA structure

15 minutes ago

To understand the function of an RNA molecule, similar to the better-known DNA and vital for cell metabolism, we need to know its three-dimensional structure. Unfortunately, establishing the shape of an RNA ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Ashy
not rated yet Mar 28, 2009
There is NO tuberculosis bacteria, there is tuberculosis mycobacteria. Mycobacterias are unicellular, aerobic saprophytes, they eat only dead decomposing tissues. They can be found everywhere, but can't do something serious to living tissue.

Other question is what killed human tissue and make it food for mycobacterias. Presence of mycobacteria in TB is only symptom, like presence of temperature in flu.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.